Biomacromolecules · 2019 · 37 citations · 23 references
PharmacyImmunologyMedicinal ChemistryAntibody EngineeringDrug DesignImmunotherapyAntibody DiscoveryAntibody Specificity EngineeringAntibody StructureAntibody-antigen RecognitionAntigen DesignTherapeutic Antibody DevelopmentAntibody Effector FunctionsAntibody Effector MechanismsCell Surface GlycoproteinsCell Surface ImmunityCell-surface InteractionsMonoclonal Antibody DiscoveryTherapeutic Antibody DesignTherapeutic Antibody Glycoengineering
Synthetic materials capable of engineering the immune system are of great relevance in the fight against cancer to replace or complement the current monoclonal antibody and cell therapy-based immunotherapeutics. Here, we report on antibody recruiting glycopolymers (ARGPs). ARGPs consist of polymeric copies of a rhamnose motif, which can bind endogenous antirhamnose antibodies present in human serum. As a proof-of-concept, we have designed ARGPs with a lipophilic end group that efficiently inserts into cell-surface membranes. We validate the specificity of rhamnose to attract antibodies from human serum to the target cell surface and demonstrate that ARGPs outperform an analogous small-molecule compound containing only one single rhamnose motif. The ARGP concept opens new avenues for the design of potent immunotherapeutics that mark target cells for destruction by the immune system through antibody-mediated effector functions.
23
Rebecca L. Siegel, Kimberly D. Miller, Ahmedin Jemal · CA A Cancer Journal for Clinicians · 2016 · 16.2K citations · Full text
Monoclonal Antibodies for Cancer Therapy
Andrew M. Scott, James P. Allison, Jedd D. Wolchok · SpringerReference · 2012 · 399 citations · Full text
Life Sciences, Immunology, Oncology +17
Selective Tumor Cell Targeting Using Low-Affinity, Multivalent Interactions
Coby B. Carlson, Patricia Mowery, Robert M. Owen et al. · ACS Chemical Biology · 2007 · 275 citations